Corticosterone alters insulin signaling in chicken muscle and liver at different steps

J Dupont, M Derouet, J Simon and M Taouis

Institut National de la Recherche Agronomique, Station de Recherches Avicoles, Laboratoire d’Endocrinologie Moléculaire et Cellulaire du Métabolisme, Centre de Tours, Nouzilly 37380, France

(Requests for offprints should be addressed to M Taouis)

Abstract

Chronic treatment with corticosterone evokes insulin resistance in chickens, a species which is already resistant to insulin compared with mammals. The in vivo effects of corticosterone on insulin signaling were investigated in chicken liver and thigh muscle in two nutritional states: basal (overnight fasted) and stimulated (30 min refeeding). Corticosterone significantly decreased specific insulin binding in liver and the amount of insulin receptor substrate–1 (IRS-1) and p85 (regulatory subunit of phosphatidylinositol (PI) 3’-kinase) in both tissues. Insulin receptor (IR) and IRS–1 mRNAs generally varied accordingly. Src homology and collagen protein (Shc) and messenger were not altered. In liver, in the basal state, the tyrosine phosphorylation of IR, IRS-1 and Shc, and the IR–associated PI 3’-kinase activity were largely decreased by corticosterone. Following refeeding the cascade was activated in control but totally inhibited in treated chickens. In muscle, as previously observed, IR and IRS–1 phosphorylation and PI 3’-kinase were not stimulated by refeeding in controls. Only the phosphorylation of Shc was increased. On this background, corticosterone decreased the basal PI 3’-kinase activity and prevented the phosphorylation of Shc in response to refeeding. In conclusion, corticosterone largely impaired insulin signaling in liver and to some extent in muscle. This should contribute to the large impairment of growth. In addition, the present studies further emphasize the peculiarities of insulin signaling in chicken muscle, which needs further investigation.

Journal of Endocrinology (1999) 162, 67–76

Introduction

Glucocorticoids have various metabolic effects. In liver, they increase glucose production (Amatruda et al. 1985), whereas, in adipose tissue and muscle, they antagonize insulin–mediated uptake and utilization of glucose (Baxter & Forshman 1972, Olefsky 1975). They also promote lipolysis by activating the cAMP-dependent hormone-sensitive lipase (Cahill 1971), although in vivo in the long term, fattening is observed. In skeletal muscle proteolytic activity is largely enhanced (Cahill 1971, Exton et al. 1976). These metabolic alterations have been attributed to a direct action of glucocorticoids or/and to an insulin resistant state via the impairment of insulin signaling (Saad et al. 1993). Insulin action is mediated through a cascade of events initiated by its binding to a transmembrane receptor, followed by an autophosphorylation and the activation of an intrinsic tyrosine kinase which phosphorylates cellular substrates. Among these substrates, members of the insulin receptor substrate (IRS) family (four at the moment) are considered as major substrates for insulin receptors (IR), which are docking proteins without enzymatic activity (Sun et al. 1991, Patti et al. 1995, Lavan et al. 1997a,b). Shc (Src homology and collagen protein), which is involved in the mitogenic signaling of a variety of tyrosine kinase growth–promoting receptors, such as those for platelet–derived growth factor, epidermal growth factor and nerve growth factor, through the ras/raf cascade, is also considered as an IRS (Pelicci et al. 1992, Sasaoka et al. 1994, Migliaccio et al. 1997).

Various proteins such as phosphatidylinositol (PI) 3’-kinase, SH2-containing phosphotyrosine phosphatase, growth factor receptor binding protein Grb2, proto-oncogene Nck, and cytosolic tyrosine kinase Fyn, promote the metabolic or mitogenic effects of insulin by associating with tyrosine phosphorylated IRS–1 (Case et al. 1994, Myers et al. 1994, White & Kahn 1994, Sanchez-Margelet et al. 1995, Saltiel 1996). Therefore, glucocorticoid–induced insulin resistance may result from an alteration at the level of one or several molecules involved in the cascade.

In the chicken, an insulin–resistant species, exogenous corticosterone (the major glucocorticoid in this species) impairs muscle growth, induces excessive fattening and further exaggerates insulin resistance. In liver, corticosterone alters IR number and tyrosine kinase activity of lectin–purified receptors (Taouis et al. 1993). In contrast, the tyrosine kinase activity of muscle receptors is not
altered by exogenous corticosterone. Recently, chicken IRS-1 gene has been cloned (Taouis et al. 1996) and IRS-1 protein has been characterized in liver and muscle (Dupont et al. 1998a). IRS-1 tyrosine phosphorylation is dependent upon the nutritional state in the liver but surprisingly not in muscle. Chicken Shc has been also partially cloned and characterized in chicken tissues (Dupont et al. 1998b). In liver and muscle, Shc associates with IR and its tyrosine phosphorylation is dependent upon the nutritional state in both tissues. Shc also associates with a PI 3'-kinase activity in both liver and muscle suggesting a metabolic role under insulin control for Shc in this species. Finally, a multimeric complex involving IR, IRS-1, Shc (mainly the 52 kDa isoform) and p85 (regulatory subunit of PI 3'-kinase) and a PI 3'-kinase activity is present in chicken tissues, at least in liver. So far the presence of this complex has not yet been demonstrated in mammals.

In order to identify the steps accounting for the corticosterone-induced insulin resistance in the chicken, the effect of daily injections of corticosterone on IR, IRS-1 and Shc tyrosine phosphorylation as well as IR-associated PI 3'-kinase activity was examined in liver and muscle. Two nutritional states were considered: basal state (overnight fasting) and stimulated state (30 min refeeding).

**Materials and Methods**

### Chemicals

Monoiodinated porcine $^{125}$I-labeled insulin was purchased from Amersham France (Les Ulis, France) and $[^{33}P]ATP$ were obtained from Isotopichim (Peyruis, France). Mono component porcine insulin was obtained from Novo Industrie Pharmaceutique (Paris, France). BSA (fraction V RIA grade), phenylmethylsulfonylfluoride, leupeptin, aprotinin, protein A-agarose, PI and corticosterone were purchased from Sigma Chemical Co. (St Louis, MO, USA). Triton X-100, SDS and nitrocellulose membrane were obtained from Bio-Rad Laboratories (Richmond, CA, USA) and pre-made polyacrylamide solution protogel was from Prolabo (National Diagnostic, Gredignon, France). Silica thin layer chromatography (TLC) plates were obtained from Carlo Erba (Val de Reuil, France). The Quick Prep total RNA extraction kit, deoxy-nucleotide triphosphate dNTP, Taq polymerase, avian myeloblastosis virus reverse transcriptase and RNase ribonuclease inhibitor were purchased from Pharmacia (Bois d’Acy, France). Nylon membranes (Hybond N+) were from Amersham. Random hexamer primers were purchased from Promega (Charbonnieres, France). Primers used for reverse transcription PCR (RT-PCR) were provided by Genosys (Cambridge, UK) and by Gibco BRL (Life Technologies, Cergy Pontoise, France). Antibodies to Shc ($\alpha$Shc), IR ($\alpha$IR) and phosphotyrosine ($\alpha$PY20) were from Transduction Laboratories (Ozyme, France). Antibodies to p85 ($\alpha$p85) were obtained from UBI (Lake Placid, NY, USA). Antibodies to IRS-1 ($\alpha$IRS-1) were purchased from UBI and Transduction Laboratories. Dithiothreitol, horseradish peroxidase conjugated with specific secondary antibodies and ECL (enhanced chemiluminescence) reagents were from Pierce (Ozyme, France).

### Animals and experimental procedures

Male broiler chickens (Shaver, Sicamen, France) were housed in a conventional floor pen. After 4 weeks, 40 chickens were placed in individual cages, fed freely with a balanced diet (3100 kcal/kg metabolizable energy and 22% protein) and exposed to a daily 14 h light period. Corticosterone was dissolved in benzyl alcohol at 37 °C and diluted in corn oil to a final concentration of 10% benzyl alcohol. At 5 weeks of age, chickens were separated into two groups of 20 animals each and treated with corticosterone (6 mg/kg per day) or placebo (1/10 benzyl alcohol in corn oil). After 1 week of treatment, insulin sensitivity was measured in ten overnight-fasted chickens (control and corticosterone-treated). They received an i.m. injection of saline or 40 µg insulin/kg and after 90 min blood samples were taken from a wing vein. The other chickens (control and corticosterone-treated animals) were separated into two groups and submitted to two nutritional states: fasted overnight, and refeed for 30 min after the overnight fast. Following blood sampling, chickens were killed by cervical dislocation. Tissues (liver and thigh muscles) were quickly removed, frozen in liquid nitrogen, ground into powder and stored at −80 °C until used.

### Determination of plasma glucose and insulin levels

Plasma glucose levels were measured by the glucose oxidase method (Glucose Beckman Analyser 2, Beckman, Palo Alto, CA, USA) and plasma insulin levels by an RIA with a guinea pig anti-porcine insulin antibody (Ab 27–6, generously provided by Dr G Rosselin, Hopital Saint-Antoine, Paris) using chicken insulin as the standard.

### Binding of insulin to liver membranes

Liver membranes were prepared as previously described (Dupont et al. 1998a). Aliquots of 50 µl crude membrane (0-4 mg/ml) were incubated overnight at 4 °C with $^{125}$I-insulin at 0-1 ng/ml in the absence or presence of increasing concentrations of unlabeled monocomponent porcine insulin (4–40 000 ng/ml). The assay was terminated by centrifugation of the tubes at 12 000 g for 3 min at 4 °C. The pellets were washed with 0-2 ml of chilled sucrose (0-25 M) and radioactivity in them counted.

### Immunoblotting and immunoprecipitation procedures

Liver and muscle protein lysates were prepared as previously described (Taouis et al. 1994, Dupont et al. 1998a).
Protein concentration of supernatants was determined using the Bradford dye binding assay kit (Bio-Rad). After normalization for protein concentration (5 mg) the supernatants were immunoprecipitated with different antibodies: αPY20 (1/200) and αIR (1/100) at 4 °C during 16 h. The immune complexes were precipitated with protein A–agarose for 1 h at 4 °C as previously described (Taouis et al. 1994, Dupont et al. 1998a). After two sequential washes using diluted buffer (1/2), the resulting pellets were boiled for 4 min in reducing Laemmli buffer containing 80 mM dithiothreitol. Proteins were resolved by SDS–PAGE and transferred to nitrocellulose membranes. Blots were blocked and probed with αIR, αIRS-1 or αShc at 1/1000 dilution. After extensive washings, immune complexes were detected with horseradish peroxidase conjugated with specific secondary antiserum followed by an ECL reaction. Band densities were estimated by using the NIH Image software (Bethesda, MD, USA).

**PI 3′-kinase assay**

PI 3′-kinase activity was determined as previously described (Levy-Toledano et al. 1994, Taouis et al. 1994). Briefly, the liver and muscle homogenates were immunoprecipitated using αIR. PI 3′-kinase activity was determined in immunoprecipitates in the presence of PI (as substrate) and labeled ATP. Following migration onto TLC plates, the level of PI phosphorylation was measured in immunoprecipitates in the presence of five sets of primers flanking: a 490 bp fragment of IRS-1 (sense: 5′ GCCCGGCCCAGGAGCTG 3′ (2630–2648) and antisense: 3′ GTACGGTTGTCCGT AACG 5′ (3120–3102)), a 383 bp fragment of IR (sense: 5′ TTTGGGATGGTTTATGAGGG 3′ (2098–2079)), a 594 bp fragment of Shc at 1/1000 dilution. After extensive washings, immune complexes were detected with horseradish peroxidase conjugated with specific secondary antiserum followed by an ECL reaction. Band densities were estimated by using the NIH Image software (Bethesda, MD, USA).

**IR, IRS-1, Shc and p85 mRNA expression**

Following RNA extraction from liver and muscle of fasted control or corticosterone-treated chickens, total RNAs were subjected to RT-PCR as previously described (Taouis et al. 1996). RT reactions were primed with random hexamers and PCR was carried out in the presence of five sets of primers flanking: a 490 bp fragment of IRS-1 (sense: 5′ GCCCGGCCAGGAGCTG 3′ (2630–2648) and antisense: 3′ GTACGGTTGTCCGT AACG 5′ (3120–3102)), a 383 bp fragment of IR (sense: 5′ TTTGGGATGGTTTATGAGGG 3′ and antisense: 3′ GCCAGGTCTCTGTGAACAAA 5′), a 344 bp fragment of p85 (sense: 5′ AACCTTCAGCTCAGGGTTG 3′ (1762–1781) and antisense: 3′ TGGCCAATGCGTT TCTTATG 5′ (2098–2079)), a 594 bp fragment of Shc (sense: 5′ GGGAGCTTGTCAATAAGCC 3′ and antisense: 5′ GAGCCATCAAAGGCAGCCATC 3′) and, as control, a 515 bp fragment of 18S RNA (sense: 5′ CTGCCCTATCAACTTTCG 3′ and antisense: 3′ GCGGTCGATCTTTATTAC 5′).

**Southern blotting**

Following RT-PCR and electrophoresis, amplified products were transferred onto nylon membranes. The blots were hybridized using 6 × 106 c.p.m. of 33P-labeled primers using T4 polynucleotide kinase. Prehybridization was carried out in a buffer containing 50% (v/v) formamide, 5 × SSC (1 × SSC=0·15 M sodium chloride, 0·015 M sodium citrate), 50% 10· Denhardt’s solution, 1% SDS and 50 mM Tris–HCl pH 7·5 for 4 h at 55 °C. Hybridization was performed in the same buffer at 55 °C for 16 h. Southern blots were revealed by autoradiography and quantified using Storm Apparatus (Molecular Dynamics).

**Statistical analysis**

For statistical comparisons between control and corticosterone-treated chickens, Student’s t-test was used.

**Results**

**Characteristics of corticosterone-treated chickens**

As previously observed (Taouis et al. 1996), overnight-fasted chickens treated with 6 mg corticosterone/kg per day for 1 week showed significant (P<0.001) reduction in body weight and a striking augmentation in liver weight (Table 1). Food intake was not affected by corticosterone treatment (Table 1).

**Effect of corticosterone treatment on glycemia, insulinemia and insulin sensitivity**

Glycemia and insulinemia were measured in control and corticosterone-treated chickens in two nutritional states (fasted for 16 h and refed for 30 min after fasting). In the fasted state, corticosterone induced a marked (P<0.05) hyperglycemia associated with a slight hyperinsulinemia as compared with control chickens (Table 2). In the refed state, in both control and treated chickens, plasma insulin (P<0.05) and glucose levels increased above the fasted state levels and were significantly higher (P<0.05) in corticosterone-treated chickens (Table 2). Ninety minutes following injection of saline or 40 µg insulin/kg, plasma glucose levels were 2·00 ± 0·08 (s.e.m.) and 0·65 ± 0·10 g/l in control chickens (P<0.05) and 2·42 ± 0·15 and

| Table 1 Effect of corticosterone treatment on body weight, food intake and liver weight after 1 week of treatment. Chickens were overnight fasted (16 h). Means ± S.E.M., n = 5  |
|---------------------------------|----------------|----------------|----------------|
| **Control**                     | **Corticosterone** |
| Body weight (g)                  | 2471±0 ± 32±1   | 1857±7 ± 33±1*** |
| Food intake (g)                  | 1258±2 ± 32±4   | 13280± 5±52     |
| Liver weight (g)                 | 4263±1 ± 61     | 7407±1 ± 75***  |
| Liver weight (% body weight)     | 1·72 ± 0±06     | 4·00 ± 0·11***  |

***P<0·001.
1·73 ± 0·30 g/l in corticosterone-treated chickens (not significant) respectively. Thus, exogenous insulin was less efficient in treated animals.

**IR number in liver and muscle of corticosterone-treated chickens**

Specific insulin binding was measured on liver membranes using monoiodinated insulin and its density was determined by Western blotting using a specific αIR. In liver, corticosterone significantly (P<0·05) reduced specific insulin binding as estimated using both techniques (Figs 1 and 2), without altering IR affinity (Fig. 1). In muscle, IR number cannot be estimated using membrane binding due to the high proportion of non-specific binding of labeled insulin (Adamo et al. 1987). In Western blot analysis using αIR we showed that corticosterone slightly reduced muscle IR density (Fig. 2) (30·0 ± 5·0 for control and 21·3 ± 3·0 arbitrary units for treated chickens as determined by densitometry using NIH Image software).

**Effect of corticosterone on IRS-1, Shc and p85 protein levels**

To determine the effect of corticosterone on IRS-1, Shc and p85 protein levels, liver and muscle lysates from fasted control and treated chickens were subjected to Western blotting and nitrocellulose membranes were blotted with αIRS-1, αShc or αp85. Band densities were quantified using the NIH Image software. In liver (Fig. 3A), IRS-1 and p85 protein amounts were decreased by 46·0 ± 12·0 and 78·9 ± 4·8% (P<0·05) respectively, in corticosterone-treated chickens as compared with control chickens. In

| Table 2 Effect of corticosterone on plasma glucose and insulin levels after 1 week of treatment in fasted (overnight) and refed (30 min) chickens. Values are means ± S.E.M. of five animals of each group |
|-------------------------------|-----------------|-----------------|-------------------|-------------------|
|                              | Control         | Corticosterone  |
|                              | Fasted          | Refed           | Fasted            | Refed             |
| Insulin (µg/l)               | 0·30 ± 0·08     | 3·60 ± 0·84     | 0·62 ± 0·15       | 7·75 ± 3·14       |
| Glucose (g/l)                | 1·99 ± 0·04     | 2·48 ± 0·15     | 3·12 ± 0·45*      | 5·41 ± 0·85†      |

*P<0·05. against control fasted.
†P<0·05 against control refed.
muscle (Fig. 3B), the same result was observed, IRS-1 and p85 protein levels were decreased by 52.5 ± 9.0 and 51.1 ± 3.3% (P<0.05) respectively, in corticosterone-treated chickens. In both tissues, corticosterone did not alter Shc protein levels (Fig. 3A and B).

**Effect of corticosterone on IR, IRS-1 and Shc mRNA expression**

To determine whether the changes in protein amounts noticed after corticosterone treatment were the consequence of RNA messenger alterations, IR, IRS-1, Shc and p85 mRNA expressions were measured. Total RNA from liver or muscle of control and treated chickens was extracted and subjected to RT-PCR, and Southern blotting was performed using the respective specific primers and probes, as described in Materials and Methods. As control, 18S RNA expression was determined in the same conditions. For each individual samples, IR, IRS-1, Shc and p85 mRNA were expressed as a ratio over 18S RNA (as percentage). In liver (Table 3), corticosterone significantly (P<0.05) reduced IR and p85 mRNA levels by 28 ± 4 and 30 ± 3% respectively. IRS-1 and Shc mRNA levels were not altered by corticosterone treatment. In muscle (Table 3), corticosterone decreased (P<0.05) IRS-1 and p85 mRNA levels by 34.9 ± 5.0 and 18.0 ± 3.0% respectively. In muscle as in liver, Shc mRNA expression was not altered by corticosterone treatment.

**Effect of corticosterone treatment on IR, IRS-1 and Shc tyrosine phosphorylation**

The impact of corticosterone on insulin signal transduction was studied by determining its effect on tyrosine phosphorylation of IR, IRS-1 and Shc in the two nutritional states (fasted and refed states). Liver and muscle lysates were immunoprecipitated with αPY20 and blotted with αIR, αIRS-1 or αShc. In liver (Fig. 4A–C), in the basal (overnight-fasted) state, corticosterone treatment significantly decreased the tyrosine phosphorylation of IR, IRS-1 and Shc by 44 ± 6, 39 ± 8 and 38 ± 5% respectively (P<0.05 for each protein). In control chickens, liver IR, IRS-1 and Shc tyrosine phosphorylation was significantly increased by refeeding as compared with the fasted state, most likely in response to the increase of plasma insulin levels (see Table 2). Corticosterone treatment completely abolished the increase in tyrosine phosphorylation of liver IR, IRS-1 and Shc associated with the refed state. In muscle (Fig. 5A and B), in the basal state, the tyrosine phosphorylation of IR, IRS-1 and Shc was similar in control and corticosterone-treated chickens. Refeeding did not alter the phosphorylation of IR, or IRS-1 in control chickens, as previously described (Dupont et al. 1998a), as well as in corticosterone-treated chickens. In contrast, in control chicken muscle, Shc tyrosine phosphorylation was significantly (P<0.05) increased by refeeding as compared with the fasted state as previously described (Dupont et al. 1998b); this effect was not detected in corticosterone-treated chickens (Fig. 5C).

![Figure 3 IRS-1, p85 and Shc protein levels in liver (A) and muscle (B) of fasted control and corticosterone-treated chickens. Samples were solubilized as described in Materials and Methods. Lysates containing 125 µg protein were resolved on SDS-PAGE (10%) and electrotransferred to nitrocellulose membranes. Blots were successively probed with αIRS-1, αp85 and αShc and bands corresponding to IRS-1 (185 kDa), p85 (85 kDa) and Shc (66, 52, 46 kDa) were revealed by ECL. n=4 animals per treatment.](image-url)
Corticosterone treatment altered PI 3’-kinase activity associated with IR

To determine the impact of changes in IR, IRS-1 and Shc tyrosine phosphorylation on a further downstream event, the PI 3’-kinase activity associated with IR was measured in liver and muscle of control and corticosterone-treated chickens in the two nutritional states. Liver and muscle lysates were immunoprecipitated with antibodies to IR and PI 3’-kinase activity measured in the resulting precipitates as described in Materials and Methods. The basal (fasted state) liver PI 3’-kinase activity (Fig. 6A) was reduced by 33 ± 7% (P<0.05) in corticosterone-treated chickens. The liver PI 3’-kinase activity significantly (P<0.05) increased in the refed state as compared with the fasted state in control chickens but this effect was abolished in corticosterone-treated chickens. In muscle (Fig. 6B), basal PI 3’-kinase activity was also significantly (P<0.05) reduced by corticosterone treatment and this at a higher extent than in liver (71 ± 9% in corticosterone-treated chickens as compared with controls). Both in control and corticosterone-treated chickens, muscle PI 3’-kinase activity was not stimulated by refeeding.

### Discussion

Corticosterone treatment impaired growth and evoked insulin resistance as evidenced by the presence of hyperglycemia and hyperinsulinemia, both in the fasting (16 h) or refed (30 min) state and by the decrease in the potency of exogenous insulin to exert its hypoglycemic effect, as previously observed (Taouis et al. 1993). The impact of corticosterone treatment on the early steps of insulin signaling (i.e. IR, IRS-1, Shc phosphorylation and PI 3’-kinase activity) has been examined in the two nutritional states. Corticosterone reduced the liver membrane IR number, which is probably the consequence of a down-regulation induced by the enhanced insulin levels found in treated chickens. In muscle, IR (seen through Western blot) was not clearly altered. In rat, dexamethasone does not alter the number of liver or muscle IRs despite an increase in plasma insulin levels (Saad et al. 1993). The origin of the discrepancy between these two species for liver IR number is unknown. We have also investigated the effect of corticosterone on the protein amounts of molecules involved in the early steps of IR cascade, such as IRS-1, Shc and p85. Corticosterone treatment decreased IRS-1 levels in chicken liver and muscle. In rat muscle, glucocorticoids have similar effects (Giorgino et al. 1993, Saad et al. 1993), whereas, in liver, dexamethasone significantly increased IRS-1 levels indicating that this treatment may antagonize the effect of insulin (Folli et al. 1996). Corticosterone also decreased p85 levels in liver and muscle, whereas no changes were noticed for Shc protein levels in both tissues. These findings corroborate previous results showing that hypoglycemic states induced by fasting or refeeding did not alter Shc levels (protein or mRNA) in liver and muscle (Dupont et al. 1998b).

Corticosterone treatment reduced basal (fasted state) IR tyrosine phosphorylation in liver and completely abolished the activating effect of refeeding. In muscle, corticosterone treatment, as for the control, did not alter IR tyrosine phosphorylation in either the fasted or refed state.

In liver, in the basal state (fasted), the amount of tyrosine phosphorylated IRS-1 and Shc was largely decreased by corticosterone. More likely, the decrease in tyrosine phosphorylation of the two substrates, IRS-1 and Shc, is subsequent to the reduced number and phosphorylation of IR despite an increase in insulin plasma levels. The modifications presently observed indicate the presence of an insulin resistance in liver. This is further demonstrated by the response to the refeeding. In control chickens, the tyrosine phosphorylation of IRS-1 and Shc was largely stimulated. In contrast, in treated chickens such stimulation was totally abolished. These alterations, added to the decrease in receptor number and phosphorylation, should lead to liver insulin resistance. In the rat, the phosphorylation of Shc has not been examined in similar conditions, at least to our knowledge.

### Table 3

Expression of IR, IRS-1, p85 and Shc in liver and muscle of control and corticosterone-treated chickens. Total RNA was extracted and subjected to RT-PCR and Southern blotting as in Materials and Methods. Incorporated radioactivity was measured using Storm Apparatus and results were expressed as a ratio over 18S RNA (%). Values are means ± S.E.M. of four chickens of each group.

<table>
<thead>
<tr>
<th></th>
<th>Liver</th>
<th>Muscle</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Corticosterone</td>
</tr>
<tr>
<td>IR</td>
<td>54.2 ± 5.0</td>
<td>39.2 ± 3.0*</td>
</tr>
<tr>
<td>IRS-1</td>
<td>14.4 ± 1.1</td>
<td>11.9 ± 0.5</td>
</tr>
<tr>
<td>Shc</td>
<td>86.8 ± 10.0</td>
<td>76.2 ± 5.6</td>
</tr>
<tr>
<td>p85</td>
<td>11.2 ± 0.9</td>
<td>7.5 ± 0.3*</td>
</tr>
</tbody>
</table>

*P<0.05.
Figure 4  IR β-subunit (A), IRS-1 (B) and Shc (C) tyrosine phosphorylation in liver of control and corticosterone-treated chickens in fasted and refeed states. Solubilized proteins (5 mg) were immunoprecipitated using αPY20. Immunoprecipitates were resolved on 10% SDS-PAGE followed by electroblotting. Blots were successively probed with αIR, αIRS-1 and αShc and bands corresponding to IRβ (95 kDa), IRS-1 (185 kDa) and Shc (52 kDa) were detected by ECL. Scanning densitometry of autoradiograms was performed on four fasted and refeed chickens of each group (control and corticosterone-treated). The data are means ± S.E.M., n=4. *P<0.05.
Figure 5 IR β-subunit (A), IRS-1 (B) and Shc (C) tyrosine phosphorylation in leg muscle of control and corticosterone-treated chickens in fasted and refed states. Solubilized proteins (5 mg) were immunoprecipitated using αPY20. Immunoprecipitates were resolved on 10% SDS-PAGE followed by electroblotting. Blots were successively probed with αIR, αIRS-1 and αShc and bands corresponding to IRβ (95 kDa), IRS-1 (185 kDa) and Shc (52 kDa) were detected by ECL. Scanning densitometry of autoradiograms was performed on four fasted and refed chickens of each group (control and corticosterone-treated). The data are means ± S.E.M. *P<0.05.
In muscle, in the basal state, the amount of tyrosine phosphorylated IRS-1 and Shc was not altered, despite the decrease in IRS-1 protein and messenger levels following corticosterone treatment. This may be the consequence of the alteration of p85 levels (protein and mRNA). However, refeeding enhanced liver PI 3'-kinase activity in control but not in corticosterone-treated chickens. This is most probably the consequence of reduced tyrosine phosphorylation of IR, IRS-1 and Shc. Recently, we demonstrated that, at least in chicken liver, PI 3'-kinase was involved in a multimeric complex including IR, IRS-1 and Shc (mainly the 52 kDa isoform, Dupont et al. 1998b). Therefore, any alteration in the level of tyrosine phosphorylation of these molecules potentially affects the association/activation of PI 3'-kinase. This type of complex has not been demonstrated in mammals and may be one of the peculiarities of insulin signaling in the chicken. In muscle, the amount of p85 subunit and the basal PI 3'-kinase activity were low after corticosterone treatment, which may contribute to a poor control of muscle metabolism and the impairment of muscle growth. However, the lack of activation of this enzyme in control and treated chickens after refeeding leads us to question the role of this enzyme in the control of muscle metabolism by insulin in this species.

In conclusion, insulin resistance and growth and metabolic perturbations induced by corticosterone are associated with several changes along the insulin signaling cascade which are likely to be of physiological importance for the development of insulin resistance. In liver, the amount of IR, IRS-1 and p85, the tyrosine phosphorylation of IR, IRS-1 and Shc, and the activation of PI 3'-kinase are decreased by corticoids. In muscle, corticosterone also induced several alterations. However, the present results provide further evidence for the presence of an apparent insulin insensitivity of insulin signaling pathways in chicken muscle. The consequences for chicken muscle physiology remain to be investigated.

Acknowledgement

This work was financially supported by a grant from AFM (Association Française contre les Myopathies).

References


Figure 6 Phosphatidyl inositol 3 phosphate (PI 3'-kinase) activity associated with IR in liver (A) and muscle (B) of control and corticosterone-treated chickens in the fasted and refeed states. Proteins were extracted and solubilized as described in Materials and Methods and immunoprecipitated with antiR. PI 3'-kinase in the washed immunoprecipitates was assayed as described in Materials and Methods. The resulting labeled lipids were extracted, separated on TLC plates, and visualized by autoradiography. [33P]phosphate incorporated into PI(3)P was quantified using phosphoimager (Molecular Dynamics) and is reported as arbitrary units. Values are means ± S.E.M. of four chickens of each group, *P<0.05.


Dupon J, Derooy M, Simon J & Taouis M 1998b Effect of nutritional state on the formation of a complex involving insulin receptor, IRS-1, the 52 kDa Shc isoform and PI 3'-kinase activity. *Biochemical Journal* 335 293–300.


Lavan BE, Lane WS & Lienhard GE 1997b The 60 kDa phosphoprotein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. *Journal of Biological Chemistry* 272 11439–11443.

